Lopinavir and tenofovir interaction observed in non‐pregnant adults altered during pregnancy
Authors:
- Engie SalamaESEngie Salama
- MAS Brookie M. Best PharmDMPMAS Brookie M. Best PharmD
- for the IMPAACT P1026s Protocol TeamFTfor the IMPAACT P1026s Protocol Team
- 12 July 2021
- journal article
- research article
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (5) , 1459-1464
Abstract
What is known and objective Tenofovir exposure is increased in non-pregnant adults when tenofovir disoproxil fumarate is coadministered with lopinavir/ritonavir. In pregnant women, tenofovir exposure is decreased. Our objective is to describe the effect of lopinavir/ritonavir on tenofovir pharmacokinetics during pregnancy. Methods Data were collected through the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) Network P1026s protocol. This was a nonrandomized, open-label, parallel-group and multicentre phase-IV prospective study in pregnant women with HIV. Intensive steady-state 24-h pharmacokinetic profiles were collected during the third trimester of pregnancy and postpartum. Tenofovir was measured in plasma using validated liquid chromatography-mass spectrometry method (quantification limit: 10 ng/ml). Statistical tests compared paired and between group pharmacokinetic data. Results and discussion In women not receiving lopinavir/ritonavir (n = 28), tenofovir AUC0-24 was 27% lower (2.2 mcg·h/ml vs 2.8 mcg·h/ml, p = 0.002) and oral clearance was 27% higher (61 L/h vs 48 L/h, p = 0.001) during the third trimester compared to paired postpartum data. In women receiving lopinavir/ritonavir (n = 10), tenofovir AUC0-24 and oral clearance were not different antepartum compared to postpartum. Women with and women without concomitant lopinavir/ritonavir displayed no significant differences in postpartum tenofovir pharmacokinetics. What is new and conclusion Tenofovir exposure during the third trimester was reduced compared to postpartum in pregnant women not receiving lopinavir/ritonavir, but not in pregnant women also receiving lopinavir/ritonavir. Our findings suggest that pregnancy confounds the expected decrease in tenofovir exposure with concomitant lopinavir/ritonavir in non-pregnant adults. These findings illustrate the need for drug-drug interaction studies in pregnant women as drug disposition differs significantly in pregnant women compared to non-pregnant adults.Keywords
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN275201800001I)
- National Institute of Allergy and Infectious Diseases (UM1AI068616, UM1AI068632, UM1AI106716)
This publication has 20 references indexed in Scilit:
- Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter studyBMC Infectious Diseases, 2013
- Pregnancy-Related Effects on Tenofovir Pharmacokinetics: a Population Study with 186 WomenAntimicrobial Agents and Chemotherapy, 2012
- Tenofovir renal proximal tubular toxicity is regulated By OAT1 and MRP4 transportersLaboratory Investigation, 2011
- Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrationsAIDS, 2010
- Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and TenofovirMolecular Pharmacology, 2007
- Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/RitonavirJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Mechanism of Active Renal Tubular Efflux of TenofovirAntimicrobial Agents and Chemotherapy, 2006
- Population Pharmacokinetics of Tenofovir in Human Immunodeficiency Virus-Infected Patients Taking Highly Active Antiretroviral TherapyAntimicrobial Agents and Chemotherapy, 2005
- Pregnancy-Induced Changes in PharmacokineticsClinical Pharmacokinetics, 2005
- Tenofovir Disoproxil FumarateClinical Pharmacokinetics, 2004